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Abstract
Background: Community-acquired pneumonia (CAP) is one of the leading causes of morbidity and mortality in the
USA. Our objective was to assess the predictive value on critical illness and disposition of a sequential Bayesian
Model that integrates Lactate and procalcitonin (PCT) for pneumonia.
Methods: Sensitivity and specificity of lactate and PCT attained from pooled meta-analysis data. Likelihood ratios
calculated and inserted in Bayesian/ Fagan nomogram to calculate posttest probabilities. Bayesian Diagnostic Gains
(BDG) were analyzed comparing pre and post-test probability. To assess the value of integrating both PCT and
Lactate in Severity of Illness Prediction we built a model that combined CURB65 with PCT as the Pre-Test markers
and later integrated the Lactate Likelihood Ratio Values to generate a combined CURB 65 + Procalcitonin + Lactate
Sequential value.
Results: The BDG model integrated a CUBR65 Scores combined with Procalcitonin (LR+ and LR-) for Pre-Test
Probability Intermediate and High with Lactate Positive Likelihood Ratios. This generated for the PCT LR+ Post-test
Probability (POSITIVE TEST) Posterior probability: 93% (95% CI [91,96%]) and Post Test Probability (NEGATIVE TEST) of:
17% (95% CI [15–20%]) for the Intermediate subgroup and 97% for the high risk sub-group POSITIVE TEST: Post-Test
probability:97% (95% CI [95,98%]) NEGATIVE TEST: Post-test probability: 33% (95% CI [31,36%]) . ANOVA analysis for
CURB 65 (alone) vs CURB 65 and PCT (LR+) vs CURB 65 and PCT (LR+) and Lactate showed a statistically significant
difference (P value = 0.013).
Conclusions: The sequential combination of CURB 65 plus PCT with Lactate yielded statistically significant results,
demonstrating a greater predictive value for severity of illness thus ICU level care.
Background
Community-acquired pneumonia (CAP) is one of the
leading causes of death in the United States. The overall
rate of CAP in adults is approximately 5.16 to 6.11 per
1000 persons per year [1, 2]. Risk factors include male
gender, African American ethnicity, older age, and med-
ical comorbidities [1]. In 2005, there were over 60,000
deaths due to pneumonia in the United States. CAP pa-
tients who require hospitalization experience higher
mortality rates. According to data from the Centers for
Medicare and Medicaid Services database, the estimated
30-day mortality rate of CAP patients requiring hospital
admission in the United States is approximately 12% [2].
Patients who present to the emergency department
with suspected CAP display a variety of symptoms in-
cluding history of cough, dyspnea, pleuritic chest pain,
acute functional or cognitive decline, fever, and tachy-
cardia. Diagnosis of CAP is typically confirmed by chest
radiography [1]. Emergency physicians must determine
the severity of the patient’s illness and decide whether
intensive care unit (ICU) level care if warranted. Clinical
decision rules such as CURB65 risk score assist in the
prediction of care needed, helping emergency physicians
in making this determination.
Clinical decision rules use signs and symptoms along
with imaging and laboratory test results to predict the
probability of a patient having a specific condition [3, 4].
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The CURB 65 Score is a widely used clinical decision
rule to determine the severity of pneumonia and clinical
estimation of management required [2]. The score
ranges from 0 to 5, receiving one point each for the
presence of Confusion, Blood Urea Nitrogen (BUN) > 19
mg/dL, Respiratory rate ≥ 30 breaths per minute, systolic
Blood pressure < 90mmHG or diastolic BP ≤ 60mmHg,
and age ≥ 65, hence the acronym CURB-65. Each score
has a corresponding estimated 30-day mortality risk per-
cent and patient disposition suggestion. A score 0–1 ad-
vises outpatient care, while a score of 2 indicates patient
discharge should be made at the physician’s discretion. A
score of 3 or more advises inpatient admission and con-
sideration for ICU admission with scores of 4 or 5 [5].
Serum biomarkers for infection are also used as pre-
dictors for sickness severity and level of care needed.
Procalcitonin (PCT) is a 116 amino acid precursor of
calcitonin, that during severe systemic inflammation,
PCT is secreted in large quantities from many tissues.
PCT serves as a specific marker for severe infections, in
particular those caused by bacterial infection. Noninfec-
tious inflammatory stimuli must be extremely severe in
order to show PCT elevations. False-negative elevations
of PCT are rare due to the fact PCT elevations are more
sustained compared to other biomarkers and occur in
neutropenic patients. PCT is detectable as soon as 2 to
4 h after a triggering event and peaks by 12 to 24 h. PCT
is eliminated with a half-life of 24–35 h in the absence of
a sustained triggering event. Higher levels of PCT are as-
sociated with more severe disease while declining levels
represent resolution of illness [6]. In patients with CAP,
monitoring of PCT may be useful as a predictor of treat-
ment outcome [7]. Studies have also found PCT can also
distinguish between gram-negative and gram-positive in-
fection, as well as between different bacterial species and
infection sites [8]. The use of PCT monitoring has led to
significantly decreased median antibiotic exposure in pa-
tients with CAP [1].
Similarly, lactate is an organic compound produced
by most tissues in the human body, most commonly
from muscle. In anaerobic conditions, lactate is the
end product of glycolysis. Lactate levels serve as a
marker for illness severity and to gauge response to
therapeutic interventions. Tissue hypoperfusion repre-
sents the most common cause of elevation. However
there are many other contributing etiologies such as
cardiac arrest, trauma, seizures, excessive muscle ac-
tivity, regional ischemia, burns and smoke inhalation,
diabetic ketoacidosis, thiamine deficiency, malignancy,
liver dysfunction, inborn errors of metabolism, and
medications [9]. Studies have shown monitoring of
blood lactate levels in patients with severe pneumonia
can serve as a prognosis indicator and to evaluate
therapeutic management [10].
Bayesian statistics is a system for describing epistemo-
logical uncertainty using the mathematical language of
probability, Bayesian statistics is a powerful “data recyc-
ling” tool of use in clinical decision making, and can be
used to compare the diagnostic quality of different
serum biomarkers, its methodology outputs the probabil-
ity of an event based on criteria related to the specific event
[4, 11–19]. Our group has developed a simple informatics
method for interpreting diagnostic impact called “Bayesian
Diagnostic Gains (BDG)”, where relative diagnostic gain
(RDG) and absolute diagnostic gain (ADG) were calculated
based on the differences deducted from pre- and posttest
probabilities (ADG= post-test – pre-test) and (RDG=
100 × post-test – pre-test/Pre-test) [11–19]. This particular
study is our first attempt at integrating BDGs in a sequen-
tial multi-item model.
The objective of this study was to assess the predictive
value of sequential Bayesian decision model that inte-
grates the CURB 65 Score, with procalcitonin (PCT) and
Lactate, this to better elucidate intensive care unit (ICU)
decision to admit in patients with pneumonia.
Methods
Sensitivity and specificity of lactate and PCT were ex-
tracted from pooled meta-analysis data [7, 20]. Likelihood
ratios were calculated using sensitivity and specificity to
quantify the possibility of particular test results [7, 20].
(Table 1) The likelihood ratios were then inserted in a
Bayesian model to calculate posttest probabilities.
The results from the CURB 65 score were used as pre-
test probability alone and combined PCT likelihood ra-
tios. To assess the value of integrating both Pro-
Calcitonin and Lactate in Severity of Illness Prediction,
we built a model that combined CURB65 with Pro-
Calcitonin as the Pre-Test markers and later integrated
the Lactate Likelihood Ratio Values to generate a com-
bined CURB 65 + Procalcitonin + Lactate Sequential
value integrated with Lactate in a Bayesian model to pre-
dict ICU admission.
The study population was risk stratified using point
score ranges using CURB 65 for pneumonia severity. A
score of 3 was considered intermediate risk of admission
and scores 4–5 were high risk. Each subpopulation was at-
tributed a risk percentage: 14% for intermediate risk and
27.8% for high risk. Procalcitonin was categorized into
two groups: < 0.5 (negative), 0.5–2.0, and > 2.0 ng/ml
Table 1 Sensitivity and Specificity of Serum Markers
Sensitivity Specificity LR+ LR-
PCT 88.0% 81.0% 4.63 0.15
Lactate 72.7% 96.2% 19.0 0.28
1PCT: Procalcitonin
1LR+: Positive Likelihood Ratio
1LR-: Negative Likelihood Ratio
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(positive), a lactate level > 2mmol/L was considered posi-
tive for the purposes of this study [7, 9]. The risk percent-
ages were used as pre-test probability in the Bayesian/
Fagan nomogram. Posttest probabilities were attained
from the nomogram after inserting the CURB 65 scores
(alone) or CURB 65 + PCT (LR+ and LR-) as pretest prob-
ability and likelihood ratios of each diagnostic test indi-
vidually (Tables 2-3).
To quantify diagnostic impact, we developed a frame-
work called “Bayesian Diagnostic Gains (BDG)”, where
relative (RDG) and Absolute (ADG) diagnostic gains
were calculated using differences between CURB 65 pre-
test results and post test probabilities. Absolute gain was
defined as the difference between pretest and post test
probability (ADG = Post- Pre). Relative gain was the per-
centage of absolute gain in relation to pretest probability
(RDG =ADG/Pre × 100).
“Number Needed to” metrics hold a more intuitive ap-
peal for clinicians than standard diagnostic accuracy
measures and these tools are being used for correctly
treating, diagnose or predict disease in certain popula-
tions [15]. The Number Needed to Treat (NNT) is the
number of patients you need to treat to prevent one
additional bad outcome. The NNT is the inverse of the
absolute risk reduction (ARR). The ARR is the absolute
difference in the rates of events between a given activity
or treatment relative to a control activity or treatment,
i.e. control event rate (CER) minus the experimental
event rate (EER), or ARR = CER - EER. The NNTs are
always rounded up to the nearest whole number and ac-
companied as standard by the 95% confidence interval.
Example: if a drug reduces the risk of a bad outcome
from 50 to 40%, the ARR = 0.5–0.4 = 0.1. Therefore, the
NNT = 1/ARR = 10. The ideal NNT would be 1 - ie all
patients treated will benefit [14].
On the basis of this concept, we used the ADG to create
a formula for the Number Needed to Diagnose (NND)
and called it Bayesian Number Needed to Diagnose (B-
NND). For this tool we took the statistical basis of the for-
mula used for the NNT, using ADG as a substitute for
ARR. Our formula is as follows: NND= 1/ADG.
ANOVA statistics were used to evaluate the
strength of association with a p value set at 0.05
(Figs. 4 and 5). R version 3.5.2 (2018-12-20) -- “Egg-
shell Igloo”. Copyright (C) 2018 The R Foundation
for Statistical Computing.
Platform: i386-w64-mingw32/i386 (32-bit) was used
for analysis and TreeAge pro 2019 for decision tree
schematization and analysis. This was an Institutional
Review Board Exempt study.
Results
Pooled diagnostic quality data obtained from meta-
analysis (Table-1) reflected a sensitivity for PCT as 88%
(95% confidence interval (CI): 80–93%) and specificity of
81% (95% CI: 67–90%) [17]. A meta-analysis for lactate
reported a sensitivity of 72.7% (95% CI: 43.4, 90.2%) and
specificity of 96.2% (95% CI: 90.6, 98.5%) [18]. This re-
sulted in Likelihood Ratios (LR) for PCT were LR+ 4.63
and LR- 0.15. LR for lactate resulted as LR+ 19.0 and
LR- 0.28.
Inserting CURB 65 risk score as pretest probability
and positive LR in Bayes Sensitivity and Specificity Se-
quential tree analysis generated a posttest probability for
PCT and lactate (Tables 2 and 3). Results for PCT inter-
mediate risk yielded a post test probability of 43.0%
(ADG = 29.0%, RDG = 207.1%). PCT high risk post test
probability was 64.0% (ADG = 36.3%, RDG = 130.6%).
Using Lactate alone as diagnostic marker on a Bayes
CURB 65 Model (Tables 4 and 5) yielded a post-test
probability for intermediate risk was 76% (ADG = 62%,
RDG = 442.9%). Lactate high risk posttest probability
was 88% (ADG = 60.2%, RDG = 216.6%).
We proceeded to build and experimental Bayesian
Gains Sequential model that integrated a CUBR65 Inter-
mediate (Int) (14% prevalence) Scores combined with
Procalcitonin (both LR+ and LR-) for Pre-Test Probabil-
ity Intermediate (43%) and High (67%) with Lactate
Positive Likelihood Ratios (Fig. 1, Fig. 2). This generated
for the PCT LR+ (Fig. 1) Post-test Probability (POSI-
TIVE TEST) Posterior probability: 93% (95% CI [91,
96%]) and Post Test Probability (NEGATIVE TEST) of:
17% (95% CI [15–20%]) for the Intermediate subgroup
and 97% for the high risk sub-group POSITIVE TEST:
Post-Test probability:97% (95% CI [95,98%]) NEGATIVE
Table 2 PCT results for Positive Likelihood Ratios (LR+)
CURB 65 Score Pretest Post Test LR+ Absolute Gain Relative Gain
Intermediate 14.0% 43.0% 29.0% 207.1%
High 27.8% 64.0% 36.3% 130.6%
1PCT: Procalcitonin
1LR+: Positive Likelihood Ratio
1LR-: Negative Likelihood Ratio
Table 3 PCT results for Negative Likelihood Ratios (LR-)
CURB 65 Score Pretest Post Test Absolute Gain Relative Gain
Intermediate 14.0% 2.0% − 12.0% 85.7%
High 27.8% 5.0% −22.8% 82.0%
1PCT: Procalcitonin
1LR+: Positive Likelihood Ratio
1LR-: Negative Likelihood Ratio
Table 4 Lactate results for Positive Likelihood Ratios (LR+)
CURB 65 Score Pretest Post Test LR+ Absolute Gain Relative Gain
Intermediate 14.0% 76.0% 62.0% 442.9%
High 27.8% 88.0% 60.2% 216.6%
1LR+: Positive Likelihood Ratio
1LR-: Negative Likelihood Ratio
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TEST: Post-test probability: 33% (95% CI [31,36%]) .
Whereas for CURB65 (Intermediate) integrated with
PCT LR- (Fig. 2) for Intermediate and High Risk
subgroups found for the intermediate risk subgroup
a POSITIVE TEST: Posterior probability: 93% (95%
CI [91,96%]) NEGATIVE TEST: Posterior probability:
17% (95% CI [15–20%]) POSITIVE TEST: Posterior
probability: 83% (95% CI [76,87%]) and NEGATIVE
TEST: Posterior probability:7% (95% CI [5,8%]).
When we applied the formula for B-NND we obtained
the following results using CURB 65 Intermediate Score
Table 5 Lactate results for Negative Likelihood Ratios (LR-)
CURB 65 Score Pretest Post Test Absolute Gain Relative Gain
Intermediate 14.0% 4.0% −10.0% 71.4%
High 27.8% 10.0% −17.8% 64.0%
1LR+: Positive Likelihood Ratio
1LR-: Negative Likelihood Ratio
Fig. 1 Sequential Bayesian Gains Model integrating CURB 65 plus Negative Procalcitonin (Pre Test) and Lactate
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(14%). When calculating B-NND for CURB 65-I inte-
grated with PCT LR + (ADG 29% yielded a B-NND of
3.45, whereas hen combining PCT (+) with Lactate (+)
ADG 79.0%) for a B-NND of 1.27 and finally, CURB-65
Intermediate and only Lactate (+) resulted in an ADG of
62% for a B-NND of 1.61 (Table 6).
ANOVA analysis for CURB 65 (alone) vs CURB 65
and PCT (LR+) vs CURB 65 and PCT (LR+) and Lactate
Fig. 2 Sequential Bayesian Gains Model integrating CURB 65 /Positive Procalcitonin (Pre Test) and Lactate
Table 6 Bayesian Number Needed to Diagnose
Pre-test Probability Post- test (LR+) ADG B-NND (rounded)
CURB 65 (14.0%) PCT (alone) 43.0% 29.0% 3.45 (3)
CURB 65 (14.0%) PCT and Lactate 93.0% 79.0% 1.27 (1)
CURB 65 (14.0%) Lactate (alone) 76.0% 62.0% 1.61 (2)
1LR+: Positive Likelihood Ratio
1ADG: Absolute Diagnosis Gain
1B-NND: Bayesian Number Needed to Diagnose
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showed a statistically significant difference (P value =
0.013), with a f-ratio value of 25.56 (Fig. 3). Whereas no
statistical significance was found in the Negative Likeli-
hood Ratio sequential model (Fig. 2).
A simple admission decision tree was developed for the
“Intermediate Risk Sub Group” based on this Sequential
Bayesian Diagnostic Gains Model (Fig. 3), where an “inter-
mediate CURB 65” integrated with a positive PCT and
Positive Lactate should warrant ICU admission, and other
integrations of procalcitonin and lactate in independent
and sequential iterations generate specific disposition de-
cisions based on post-test probability assessments.
Discussion
According to the CURB 65 score, high risk patients are
those that should be considered for an admission to the
ICU. The Bayesian statistical model demonstrated a su-
perior diagnostic gains in predicting ICU admissions
with the independent integration of lactate compared to
Procalcitonin. Absolute diagnostic gain was greater for
both lactate and PCT in the intermediate risk category,
showing a more important gain in the lactate subgroup.
However, in high risk patients relative gain and absolute
gains were not a meaningful, but still favoring Lactate.
The sequential integration of Pro-Calcitonin (LR+)
plus CURB 65 combined with Lactate demonstrated a
high post-test probability, almost similar in intermediate
(93%) and high pretest probability (97%) showing an ab-
solute difference of only 4%, and supporting its use more
meaningfully in the intermediate pre-test subgroups, this
demonstrated a statistically significant value (Fig. 4).
Confirming that patient-centered clinical decision mak-
ing should be able to integrate several clinical items in
an effort to adequately predict severity of illness and
eventual ICU resource utilization.
These results are important in that they suggest Lactate in-
tegrated with the CURB 65/ PCT (LR+) have a greater pre-
dictive value for ICU admissions in patients with pneumonia.
Fig. 3 Sequential Bayesian Admission/ Disposition Decision Tree. ICU: Intensive Care Unit. PCU: Step Down of Progressive Care Unit. Obs:
Observation Unit. *PCT: Procalcitonin
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Whereas, no statistically significant sequential improvement
was found in the LR (−) predictive model (Fig. 5).
Our Decision Support Tree (Fig. 3) integrates these
findings, suggesting an integrated approach to admission
decision making that contemplates CURB65, PCT and
Lactate in admission decision making.
The cost effectiveness of this decision process needs to
be further elucidated, as it is an enticing concept for
health economics. From a research stand point, by math-
ematically integrating results from strong but independ-
ent research studies and performing a “data recycling
study” one can develop hypothesis generating and deci-
sion support tools, without costly investments in inde-
pendent studies, our group has produced and validated
this model in multiple other studies, [4, 15–19] thus cre-
ating a new reference instrument for evaluating
integrating independent data results and as a hypothesis
generating tool. Clinically this process can also justify a
positive health economics impact. In a 2013 study per-
formed by Smith et al. found PCT protocols cost
$10–$54 more per patient than usual care in CAP pa-
tients [21]. Lactate level costs vary from hospital to hos-
pital, with an average test of costs $78 [22]. The average
cost of Intensive Care Unit stay in the United States
ranges around >$4000/ day, thus by properly integrating
the combination of CURB65, Procalcitonin and Lactate
systems can me reliably predict need for ICU stay and
potentially save thousands of dollars on individual not
recommended ICU admissions, and very likely saving
millions of dollars on unnecessary ICU admissions at a
more macro level. A more comprehensive value-based
and cost effective analysis will be performed in a future
Fig. 4 ANOVA for Sequential Bayesian Diagnostic Grains of CURB 65 Alone (Group-1) / CURB 65 + PCT (LR+) (Group-2) and CURB65 + PCT +
Lactate Integrated (LR+) (Group-3)
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study that also prospectively contemplates disposition mak-
ing and decision support. Furthermore, future studies should
take into consideration the cost of measuring PCT or lactate
when choosing which test to use in guiding patient care and
decision making. Currently our group is generating a valid-
ation study that integrates real (retrospective) patient data in
assessing decision making effectiveness and cost.
Limitations of this study include the need for prospect-
ive validation of this method given that our study repre-
sents a mathematical estimation. Our study is based on
meta-analysis data that needs to be further validated.
Other limitations include but are not limited to individual
systems issues that influence admission decisions which
would limit our study’s generalizability. The point in time
at which the blood level of these biomarkers are obtained
is also a limitation due to the wide variation of values at
different points in the disease process.
Conclusion
Bayesian statistical model demonstrated a superior inde-
pendent diagnostic gain in predicting ICU admissions with
the integration of lactate to the CURB 65 risk score. The se-
quential combination of CURB 65 plus Procalcitonin with
Lactate yielded statistically significant results, showing that
the integration of Lactate with the CURB 65 Risk Score
plus Procalcitonin had a greater predictive value for severity
of illness thus ICU level care, thus suggesting that decision
support tools be able to combine these various clinical
items in a final decision pathway for the prediction of ICU
admissions in patients with pneumonia.
Fig. 5 ANOVA for Sequential Bayesian Diagnostic Grains of CURB 65 Alone (Group-1) / CURB 65 + PCT (LR-) (Group-2) and CURB65 + PCT + Lactate
Integrated (LR-) (Group-3). *PCT: Procalcitonin
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